You can filter the data below or go straight to the results. Descriptions of the various cell types we distribute, such as CPLs and LCLs, can be found here. Information on ordering biomaterials can be found here.
To share these results with others, including any filters applied, click the box below to copy a link to this page to your clipboard:
Cell type descriptions can be found here. Note that CPLs are ideal for making iPSCs.
Distribution | Subjects | DNA Available* | Plasma | LCLs | CPLs** | Whole Blood |
---|---|---|---|---|---|---|
Nicotine Dependence | 15,593 |
13,230 (85%) |
2,467 (16%) |
7,716 (49%) |
12,637 (81%) |
4,409 (28%) |
Total | 15,593 |
13,230 (85%) |
2,467 (16%) |
7,716 (49%) |
12,637 (81%) |
4,409 (28%) |
*DNA Available refers to subjects for which DNA is available from at least one of LCLs, CPLs or Whole Blood.
**Note that CPLs are ideal for making iPSCs.
Item | Value |
---|---|
Subjects | 15,593 |
DNA Available | 13,230 (85%) |
Instrument: DSM-IV | 8,691 (56%) |
Instrument: DSM-III-R | 115 (1%) |
Instrument: Unknown | 6,787 (44%) |
Females / Males / Unknown | 8,636 (55%) / 6,929 (44%) / 28 (0%) |
Age | Average: 43.1, Min: 12, Max: 88 |
Race/Ethnicity | Subjects |
---|---|
White Non-Hispanic | 9,891 (63%) |
African-American | 5,085 (33%) |
Other | 453 ( 3%) |
White Hispanic | 91 ( 1%) |
Asian | 50 ( 0%) |
Missing | 17 ( 0%) |
American Indian | 6 ( 0%) |
Cell type descriptions can be found here. Note that CPLs are ideal for making iPSCs.
Cell Type | Subjects | Subjects with 2+ Vials | 5+ Vials | 10+ Vials |
---|---|---|---|---|
LCL | 7,716 (49%) |
7,715 (49%) |
7,701 (49%) |
5,607 (36%) |
CPL | 12,637 (81%) |
11,266 (72%) |
1 ( 0%) |
0 ( 0%) |
LCL gDNA | 7,493 (48%) |
7,448 (48%) |
1,765 (11%) |
38 ( 0%) |
WB gDNA | 6,735 (43%) |
165 ( 1%) |
0 ( 0%) |
0 ( 0%) |
Plasma | 2,467 (16%) |
1,078 ( 7%) |
1,067 ( 7%) |
15 ( 0%) |
Whole Blood | 4,409 (28%) |
1,019 ( 7%) |
1 ( 0%) |
0 ( 0%) |
Disease | Affected* | Unaffected | Other |
---|---|---|---|
Alcohol Dependence | 1,592 (10%) |
6,815 (44%) |
7,186 (46%) |
Cannabis Dependence | 858 ( 6%) |
7,773 (50%) |
6,962 (45%) |
Cocaine Dependence | 436 ( 3%) |
8,302 (53%) |
6,855 (44%) |
Nicotine Dependence | 5,280 (34%) |
3,441 (22%) |
6,872 (44%) |
Opioid Dependence | 120 ( 1%) |
6,835 (44%) |
8,638 (55%) |
Other Drug Dependence | 244 ( 2%) |
8,484 (54%) |
6,865 (44%) |
Sedative Dependence | 32 ( 0%) |
3,544 (23%) |
12,017 (77%) |
Stimulant Dependence | 75 ( 0%) |
3,501 (22%) |
12,017 (77%) |
Alcohol Abuse | 535 ( 3%) |
2,311 (15%) |
12,747 (82%) |
Cannabis Abuse | 308 ( 2%) |
3,269 (21%) |
12,016 (77%) |
Cocaine Abuse | 58 ( 0%) |
3,517 (23%) |
12,018 (77%) |
Opioid Abuse | 29 ( 0%) |
3,546 (23%) |
12,018 (77%) |
Other Drug Abuse | 129 ( 1%) |
3,447 (22%) |
12,017 (77%) |
Sedative Abuse | 33 ( 0%) |
3,543 (23%) |
12,017 (77%) |
Stimulant Abuse | 51 ( 0%) |
3,525 (23%) |
12,017 (77%) |
Alcohol Use Disorder | 0 ( 0%) |
0 ( 0%) |
15,593 (100%) |
Cannabis Use Disorder | 0 ( 0%) |
0 ( 0%) |
15,593 (100%) |
Cocaine Use Disorder | 0 ( 0%) |
0 ( 0%) |
15,593 (100%) |
Nicotine Use Disorder | 0 ( 0%) |
0 ( 0%) |
15,593 (100%) |
Opioid Use Disorder | 0 ( 0%) |
0 ( 0%) |
15,593 (100%) |
Other Use Disorder | 0 ( 0%) |
0 ( 0%) |
15,593 (100%) |
Sedative Use Disorder | 0 ( 0%) |
0 ( 0%) |
15,593 (100%) |
Stimulant Use Disorder | 0 ( 0%) |
0 ( 0%) |
15,593 (100%) |
*The definition of affected depends on the study and is shown in the study breakdown below (unless hidden via the option above).
Cell type descriptions can be found here. Note that CPLs are ideal for making iPSCs.
Study | Name | PI | Definition of Affected | N | DNA Available* | Plasma | LCLs | CPLs** | Whole Blood |
---|---|---|---|---|---|---|---|---|---|
NicSNP | The NicSNP Study | Laura Bierut | FTND >= 4 | 1,927 |
1,927 (100%) |
515 (27%) |
1,340 (70%) |
1,880 (98%) |
773 (40%) |
2 | Mapping Susceptibility Genes for Nicotine Dependence | Ming D. Li | DSM Nicotine Dependence or FTND>=4 | 2,803 |
1,962 (70%) |
0 ( 0%) |
1,961 (70%) |
1,835 (65%) |
0 ( 0%) |
6 | The Genetics of Vulnerability to Nicotine | Pamela Madden | DSM Nicotine Dependence or FTND>=4 | 3,446 |
2,344 (68%) |
0 ( 0%) |
2,330 (68%) |
2,156 (63%) |
30 ( 1%) |
9 | Differentiation of Phenotypes for Smoking: Administrative Supplement to Join NIDA Genetics Consortium | Ovide Pomerleau | DSM Nicotine Dependence or FTND>=4 or 5 cigs/day for 5 years and current 6 months | 1,565 |
1,540 (98%) |
0 ( 0%) |
607 (39%) |
1,502 (96%) |
887 (57%) |
10 | Pharmacokinetics of Nicotine in Twins | Gary Swan | DSM Nicotine Dependence or FTND>=4 | 124 |
62 (50%) |
0 ( 0%) |
62 (50%) |
60 (48%) |
0 ( 0%) |
15 | Nicotine Dependence | Laura Bierut | DSM Nicotine Dependence or FTND>=4 | 2,146 |
1,813 (84%) |
876 (41%) |
854 (40%) |
1,761 (82%) |
1,131 (53%) |
16 | Nicotine Dependence | Mark Leppert | DSM Nicotine Dependence or FTND>=4 | 917 |
917 (100%) |
2 ( 0%) |
359 (39%) |
821 (90%) |
535 (58%) |
27 | The Genetic Study of Nicotine Dependence in African Americans (AAND) | Laura Bierut | DSM Nicotine Dependence or FTND>=4 | 1,792 |
1,792 (100%) |
206 (11%) |
194 (11%) |
1,753 (98%) |
1,032 (58%) |
35 | Genetically Informative Smoking Cessation Trial | Li-Shiun Chen | Active smoking (Cigarettes Per Day [CPD] ≥5) and exhaled Carbon Monoxide [CO] ≥8 ppm | 873 |
873 (100%) |
868 (99%) |
9 ( 1%) |
869 (100%) |
21 ( 2%) |
Total | 15,593 |
13,230 (85%) |
2,467 (16%) |
7,716 (49%) |
12,637 (81%) |
4,409 (28%) |
*DNA Available refers to subjects for which DNA is available from at least one of LCLs, CPLs or Whole Blood.
**Note that CPLs are ideal for making iPSCs.
cell_file
version: 2024-09-10-11-54